Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCNH | P51946 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 4/20 | 0.36 |
| ▸ | AKT2 | P31751 | 4/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 11/20 | 0.35 |
| ▸ | CCR7 | P32248 | 4/20 | 0.34 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29536592 | 1.00 | CDK1 (0.39) | CDK1KDRCA2CDK2CDK4 | |
| SCHEMBL25227902 | 1.00 | CDK1 (0.39) | CDK1KDRCA2CDK2CDK4 | |
| SCHEMBL25271264 | 0.80 | AKT1 (0.34) | AKT1AKT2 | |
| SCHEMBL29537498 | 0.80 | AKT1 (0.34) | AKT1AKT2 | |
| SCHEMBL25227024 | 0.80 | AKT1 (0.39) | CDK2AKT1AKT2 | |
| SCHEMBL29536669 | 0.80 | AKT1 (0.39) | CDK2AKT1AKT2 | |
| SCHEMBL25271560 | 0.79 | AKT1 (0.39) | CDK1KDRCDK2AKT1AKT2 | |
| SCHEMBL29536658 | 0.79 | AKT1 (0.39) | CDK1KDRCDK2AKT1AKT2 | |
| SCHEMBL31344333 | 0.77 | HASPIN (0.36) | AKT1AKT2 | |
| SCHEMBL25222377 | 0.77 | AKT1 (0.34) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4192582-A1 | KINASE INHIBITORS AND USES THEREOF | ABM Therapeutics Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | CDK1 187/4885KDR 209/4885CA2 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.